APA

Kubitza D., Becka M., Mueck W., Halabi A., Maatouk H., Klause N., Lufft V., Wand D. D., Philipp T. & Bruck H. (20110224). Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. : British journal of clinical pharmacology.

Chicago

Kubitza Dagmar, Becka Michael, Mueck Wolfgang, Halabi Atef, Maatouk Haidar, Klause Norbert, Lufft Volkmar, Wand Dominic D, Philipp Thomas and Bruck Heike. 20110224. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. : British journal of clinical pharmacology.

Harvard

Kubitza D., Becka M., Mueck W., Halabi A., Maatouk H., Klause N., Lufft V., Wand D. D., Philipp T. and Bruck H. (20110224). Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. : British journal of clinical pharmacology.

MLA

Kubitza Dagmar, Becka Michael, Mueck Wolfgang, Halabi Atef, Maatouk Haidar, Klause Norbert, Lufft Volkmar, Wand Dominic D, Philipp Thomas and Bruck Heike. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. : British journal of clinical pharmacology. 20110224.